Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

European Research Council grant · Finished

Re-TauAD Repurposing a human drug to treat Alzheimer’s disease

Coordinator
Deutsches Zentrum Fur Neurodegenerative Erkrankungen eV, Germany
Runs
1 June 2022 to 30 November 2023
Status
Finished
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101069214

What the project is doing

In the project's own words, from its summary on CORDIS.

Alzheimer’s disease is a major cause of disability among older adults and represents substantial financial and human costs to patients, families and societies worldwide. Currently there is no cure for Alzheimer’s disease. Thus, novel effective treatments need to be developed that target the root causes of Alzheimer’s disease, in particular the pathogenic accumulation of the protein tau. During our ERC project, we achieved a breakthrough by demonstrating that an approved human drug efficiently inhibits pathogenic tau accumulation in several pre-clinical assays.

The identified FDA/EMA-approved small molecule is orally bioavailable, safe in humans and reaches the brain at high concentrations. It is the aim of this proof of concept project to provide further pre-clinical validation of the drug and to pursue the needed steps towards IPR protection and commercialization. Because no disease-modifying therapy currently exists for AD, bringing the novel repurposed drug closer to the market promises an outstanding high gain.

Topics

Who is involved

OrganisationCityCountryRole
Deutsches Zentrum Fur Neurodegenerative Erkrankungen eVBonnGermanyCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI